Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

Clifton Bingham, R. John Looney, Atul Deodhar, Neal A Halsey, Maria Greenwald, Christine Codding, Benjamin Trzaskoma, Flavius Martin, Sunil Agarwal, Ariella Kelman

Research output: Contribution to journalArticle

Abstract

Objective. To examine immunization responses in patients with rheumatoid arthritis (RA) treated with rituximab and to investigate the effects of rituximab-induced CD20+ B cell depletion on immune responses to tetanus toxoid (T cell-dependent antigen), pneumococcal polysaccharide (T cell-independent antigen), and keyhole limpet hemocyanin (KLH) (neoantigen) and on delayed-type hypersensitivity (DTH). Methods. In a controlled trial, we enrolled 103 patients with active RA receiving a stable dose of methotrexate (MTX). Tetanus toxoid, pneumococcal polysaccharide, and KLH vaccines as well as a Candida albicans skin test were administered to 1 group of patients receiving rituximab plus MTX (called rituximab-treated patients) for 36 weeks and to 1 group of patients receiving MTX alone for 12 weeks. The primary end point was the proportion of patients with a ≥4-fold rise in antitetanus IgG levels. Antitetanus, antipneumococcal, and anti-KLH serum IgG levels were measured prior to and 4 weeks following vaccine administration. The DTH response to C albicans was measured 2-3 days following placement. Results. Responses to tetanus toxoid vaccine (≥4-fold rise) were similar in both groups (39.1% of rituximab-treated patients and 42.3% of patients treated with MTX alone). The ability to maintain a positive DTH response to the C albicans skin test was comparable in both groups (77.4% of rituximab-treated patients and 70% of patients treated with MTX alone), showing no effect of rituximab treatment. Rituximab-treated patients had decreased responses to pneumococcal polysaccharide vaccine (57% of patients had a 2-fold rise in titer in response to ≥1 serotype, compared with 82% of patients treated with MTX alone) and to KLH vaccine (47% of patients had detectable anti-KLH IgG, compared with 93% of patients treated with MTX alone). Conclusion. Recall responses to the T cell-dependent protein antigen tetanus toxoid as well as DTH responses were preserved in rituximab-treated RA patients 24 weeks after treatment. Responses to neoantigen (KLH) and T cell-independent responses to pneumococcal vaccine were decreased, but many patients were able to mount responses. These data suggest that polysaccharide and primary immunizations should be administered prior to rituximab infusions to maximize responses.

Original languageEnglish (US)
Pages (from-to)64-74
Number of pages11
JournalArthritis and Rheumatism
Volume62
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Controlled Clinical Trials
Immunization
Rheumatoid Arthritis
Methotrexate
Tetanus Toxoid
Delayed Hypersensitivity
Polysaccharides
T-Lymphocytes
Pneumococcal Vaccines
Rituximab
Vaccines
Immunoglobulin G
Skin Tests
T Independent Antigens
Antigens
Candida albicans

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Immunization responses in rheumatoid arthritis patients treated with rituximab : Results from a controlled clinical trial. / Bingham, Clifton; Looney, R. John; Deodhar, Atul; Halsey, Neal A; Greenwald, Maria; Codding, Christine; Trzaskoma, Benjamin; Martin, Flavius; Agarwal, Sunil; Kelman, Ariella.

In: Arthritis and Rheumatism, Vol. 62, No. 1, 01.2010, p. 64-74.

Research output: Contribution to journalArticle

Bingham, C, Looney, RJ, Deodhar, A, Halsey, NA, Greenwald, M, Codding, C, Trzaskoma, B, Martin, F, Agarwal, S & Kelman, A 2010, 'Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial', Arthritis and Rheumatism, vol. 62, no. 1, pp. 64-74. https://doi.org/10.1002/art.25034
Bingham, Clifton ; Looney, R. John ; Deodhar, Atul ; Halsey, Neal A ; Greenwald, Maria ; Codding, Christine ; Trzaskoma, Benjamin ; Martin, Flavius ; Agarwal, Sunil ; Kelman, Ariella. / Immunization responses in rheumatoid arthritis patients treated with rituximab : Results from a controlled clinical trial. In: Arthritis and Rheumatism. 2010 ; Vol. 62, No. 1. pp. 64-74.
@article{470e35dbf7a94ba180e5b2bce08ca5a5,
title = "Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial",
abstract = "Objective. To examine immunization responses in patients with rheumatoid arthritis (RA) treated with rituximab and to investigate the effects of rituximab-induced CD20+ B cell depletion on immune responses to tetanus toxoid (T cell-dependent antigen), pneumococcal polysaccharide (T cell-independent antigen), and keyhole limpet hemocyanin (KLH) (neoantigen) and on delayed-type hypersensitivity (DTH). Methods. In a controlled trial, we enrolled 103 patients with active RA receiving a stable dose of methotrexate (MTX). Tetanus toxoid, pneumococcal polysaccharide, and KLH vaccines as well as a Candida albicans skin test were administered to 1 group of patients receiving rituximab plus MTX (called rituximab-treated patients) for 36 weeks and to 1 group of patients receiving MTX alone for 12 weeks. The primary end point was the proportion of patients with a ≥4-fold rise in antitetanus IgG levels. Antitetanus, antipneumococcal, and anti-KLH serum IgG levels were measured prior to and 4 weeks following vaccine administration. The DTH response to C albicans was measured 2-3 days following placement. Results. Responses to tetanus toxoid vaccine (≥4-fold rise) were similar in both groups (39.1{\%} of rituximab-treated patients and 42.3{\%} of patients treated with MTX alone). The ability to maintain a positive DTH response to the C albicans skin test was comparable in both groups (77.4{\%} of rituximab-treated patients and 70{\%} of patients treated with MTX alone), showing no effect of rituximab treatment. Rituximab-treated patients had decreased responses to pneumococcal polysaccharide vaccine (57{\%} of patients had a 2-fold rise in titer in response to ≥1 serotype, compared with 82{\%} of patients treated with MTX alone) and to KLH vaccine (47{\%} of patients had detectable anti-KLH IgG, compared with 93{\%} of patients treated with MTX alone). Conclusion. Recall responses to the T cell-dependent protein antigen tetanus toxoid as well as DTH responses were preserved in rituximab-treated RA patients 24 weeks after treatment. Responses to neoantigen (KLH) and T cell-independent responses to pneumococcal vaccine were decreased, but many patients were able to mount responses. These data suggest that polysaccharide and primary immunizations should be administered prior to rituximab infusions to maximize responses.",
author = "Clifton Bingham and Looney, {R. John} and Atul Deodhar and Halsey, {Neal A} and Maria Greenwald and Christine Codding and Benjamin Trzaskoma and Flavius Martin and Sunil Agarwal and Ariella Kelman",
year = "2010",
month = "1",
doi = "10.1002/art.25034",
language = "English (US)",
volume = "62",
pages = "64--74",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Immunization responses in rheumatoid arthritis patients treated with rituximab

T2 - Results from a controlled clinical trial

AU - Bingham, Clifton

AU - Looney, R. John

AU - Deodhar, Atul

AU - Halsey, Neal A

AU - Greenwald, Maria

AU - Codding, Christine

AU - Trzaskoma, Benjamin

AU - Martin, Flavius

AU - Agarwal, Sunil

AU - Kelman, Ariella

PY - 2010/1

Y1 - 2010/1

N2 - Objective. To examine immunization responses in patients with rheumatoid arthritis (RA) treated with rituximab and to investigate the effects of rituximab-induced CD20+ B cell depletion on immune responses to tetanus toxoid (T cell-dependent antigen), pneumococcal polysaccharide (T cell-independent antigen), and keyhole limpet hemocyanin (KLH) (neoantigen) and on delayed-type hypersensitivity (DTH). Methods. In a controlled trial, we enrolled 103 patients with active RA receiving a stable dose of methotrexate (MTX). Tetanus toxoid, pneumococcal polysaccharide, and KLH vaccines as well as a Candida albicans skin test were administered to 1 group of patients receiving rituximab plus MTX (called rituximab-treated patients) for 36 weeks and to 1 group of patients receiving MTX alone for 12 weeks. The primary end point was the proportion of patients with a ≥4-fold rise in antitetanus IgG levels. Antitetanus, antipneumococcal, and anti-KLH serum IgG levels were measured prior to and 4 weeks following vaccine administration. The DTH response to C albicans was measured 2-3 days following placement. Results. Responses to tetanus toxoid vaccine (≥4-fold rise) were similar in both groups (39.1% of rituximab-treated patients and 42.3% of patients treated with MTX alone). The ability to maintain a positive DTH response to the C albicans skin test was comparable in both groups (77.4% of rituximab-treated patients and 70% of patients treated with MTX alone), showing no effect of rituximab treatment. Rituximab-treated patients had decreased responses to pneumococcal polysaccharide vaccine (57% of patients had a 2-fold rise in titer in response to ≥1 serotype, compared with 82% of patients treated with MTX alone) and to KLH vaccine (47% of patients had detectable anti-KLH IgG, compared with 93% of patients treated with MTX alone). Conclusion. Recall responses to the T cell-dependent protein antigen tetanus toxoid as well as DTH responses were preserved in rituximab-treated RA patients 24 weeks after treatment. Responses to neoantigen (KLH) and T cell-independent responses to pneumococcal vaccine were decreased, but many patients were able to mount responses. These data suggest that polysaccharide and primary immunizations should be administered prior to rituximab infusions to maximize responses.

AB - Objective. To examine immunization responses in patients with rheumatoid arthritis (RA) treated with rituximab and to investigate the effects of rituximab-induced CD20+ B cell depletion on immune responses to tetanus toxoid (T cell-dependent antigen), pneumococcal polysaccharide (T cell-independent antigen), and keyhole limpet hemocyanin (KLH) (neoantigen) and on delayed-type hypersensitivity (DTH). Methods. In a controlled trial, we enrolled 103 patients with active RA receiving a stable dose of methotrexate (MTX). Tetanus toxoid, pneumococcal polysaccharide, and KLH vaccines as well as a Candida albicans skin test were administered to 1 group of patients receiving rituximab plus MTX (called rituximab-treated patients) for 36 weeks and to 1 group of patients receiving MTX alone for 12 weeks. The primary end point was the proportion of patients with a ≥4-fold rise in antitetanus IgG levels. Antitetanus, antipneumococcal, and anti-KLH serum IgG levels were measured prior to and 4 weeks following vaccine administration. The DTH response to C albicans was measured 2-3 days following placement. Results. Responses to tetanus toxoid vaccine (≥4-fold rise) were similar in both groups (39.1% of rituximab-treated patients and 42.3% of patients treated with MTX alone). The ability to maintain a positive DTH response to the C albicans skin test was comparable in both groups (77.4% of rituximab-treated patients and 70% of patients treated with MTX alone), showing no effect of rituximab treatment. Rituximab-treated patients had decreased responses to pneumococcal polysaccharide vaccine (57% of patients had a 2-fold rise in titer in response to ≥1 serotype, compared with 82% of patients treated with MTX alone) and to KLH vaccine (47% of patients had detectable anti-KLH IgG, compared with 93% of patients treated with MTX alone). Conclusion. Recall responses to the T cell-dependent protein antigen tetanus toxoid as well as DTH responses were preserved in rituximab-treated RA patients 24 weeks after treatment. Responses to neoantigen (KLH) and T cell-independent responses to pneumococcal vaccine were decreased, but many patients were able to mount responses. These data suggest that polysaccharide and primary immunizations should be administered prior to rituximab infusions to maximize responses.

UR - http://www.scopus.com/inward/record.url?scp=74849096560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74849096560&partnerID=8YFLogxK

U2 - 10.1002/art.25034

DO - 10.1002/art.25034

M3 - Article

C2 - 20039397

AN - SCOPUS:74849096560

VL - 62

SP - 64

EP - 74

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 1

ER -